Enzo Biochem Inc (ENZ)

$1.12

+0.01

(+0.9%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $1.10
    $1.13
    $1.12
    downward going graph

    1.79%

    Downside

    Day's Volatility :2.65%

    Upside

    0.88%

    downward going graph
  • $0.99
    $1.50
    $1.12
    downward going graph

    11.6%

    Downside

    52 Weeks Volatility :33.99%

    Upside

    25.33%

    downward going graph

Returns

PeriodEnzo Biochem IncIndex (Russel 2000)
3 Months
-0.88%
0.0%
6 Months
-15.79%
0.0%
1 Year
-23.81%
0.0%
3 Years
-69.57%
-22.3%

Highlights

Market Capitalization
57.6M
Book Value
$1.35
Earnings Per Share (EPS)
-0.35
PEG Ratio
0.0
Wall Street Target Price
5.5
Profit Margin
134.17%
Operating Margin TTM
-25.47%
Return On Assets TTM
-12.77%
Return On Equity TTM
-39.9%
Revenue TTM
33.3M
Revenue Per Share TTM
0.66
Quarterly Revenue Growth YOY
7.199999999999999%
Gross Profit TTM
11.6M
EBITDA
-15.4M
Diluted Eps TTM
-0.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Enzo Biochem Inc(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 391.07%

Current $1.12
Target $5.50

Company Financials

FY18Y/Y Change
Revenue
104.7M
↓ 2.87%
Net Income
-10.3M
↑ 312.18%
Net Profit Margin
-9.86%
↓ 7.54%
FY19Y/Y Change
Revenue
81.2M
↓ 22.48%
Net Income
-98.8M
↑ 857.09%
Net Profit Margin
-121.7%
↓ 111.84%
FY20Y/Y Change
Revenue
76.0M
↓ 6.34%
Net Income
-33.9M
↓ 65.69%
Net Profit Margin
-44.58%
↑ 77.12%
FY21Y/Y Change
Revenue
117.7M
↑ 54.87%
Net Income
3.4M
↓ 110.11%
Net Profit Margin
2.91%
↑ 47.49%
FY22Y/Y Change
Revenue
107.1M
↓ 9.05%
Net Income
-22.6M
↓ 759.21%
Net Profit Margin
-21.09%
↓ 24.0%
FY23Y/Y Change
Revenue
31.1M
↓ 70.99%
Net Income
20.3M
↓ 189.86%
Net Profit Margin
65.32%
↑ 86.41%
Q1 FY23Q/Q Change
Revenue
16.3M
↓ 10.6%
Net Income
-10.7M
↓ 14.26%
Net Profit Margin
-65.22%
↑ 2.78%
Q2 FY23Q/Q Change
Revenue
16.1M
↓ 1.41%
Net Income
-14.7M
↑ 38.22%
Net Profit Margin
-91.44%
↓ 26.22%
Q3 FY23Q/Q Change
Revenue
31.1M
↑ 92.84%
Net Income
20.3M
↓ 237.74%
Net Profit Margin
65.32%
↑ 156.76%
Q4 FY23Q/Q Change
Revenue
7.8M
↓ 74.87%
Net Income
-6.6M
↓ 132.61%
Net Profit Margin
-84.76%
↓ 150.08%
Q1 FY24Q/Q Change
Revenue
8.6M
↑ 9.57%
Net Income
-3.1M
↓ 53.73%
Net Profit Margin
-35.79%
↑ 48.97%
Q2 FY24Q/Q Change
Revenue
8.0M
↓ 6.21%
Net Income
-3.0M
↓ 1.34%
Net Profit Margin
-37.65%
↓ 1.86%
FY18Y/Y Change
Total Assets
101.7M
↓ 5.58%
Total Liabilities
20.5M
↑ 9.29%
FY19Y/Y Change
Total Assets
106.6M
↑ 4.9%
Total Liabilities
20.6M
↑ 0.36%
FY20Y/Y Change
Total Assets
112.5M
↑ 5.53%
Total Liabilities
54.2M
↑ 162.75%
FY21Y/Y Change
Total Assets
113.7M
↑ 1.02%
Total Liabilities
45.1M
↓ 16.71%
FY22Y/Y Change
Total Assets
95.9M
↓ 15.69%
Total Liabilities
41.4M
↓ 8.23%
FY23Y/Y Change
Total Assets
121.9M
↑ 27.15%
Total Liabilities
43.4M
↑ 4.89%
Q1 FY23Q/Q Change
Total Assets
76.5M
↓ 10.27%
Total Liabilities
43.6M
↑ 8.49%
Q2 FY23Q/Q Change
Total Assets
72.1M
↓ 5.74%
Total Liabilities
53.1M
↑ 21.8%
Q3 FY23Q/Q Change
Total Assets
121.9M
↑ 69.13%
Total Liabilities
43.4M
↓ 18.28%
Q4 FY23Q/Q Change
Total Assets
106.3M
↓ 12.78%
Total Liabilities
32.0M
↓ 26.22%
Q1 FY24Q/Q Change
Total Assets
99.1M
↓ 6.8%
Total Liabilities
28.3M
↓ 11.65%
Q2 FY24Q/Q Change
Total Assets
93.5M
↓ 5.66%
Total Liabilities
24.4M
↓ 13.65%
FY18Y/Y Change
Operating Cash Flow
-2.7M
↑ 1234.15%
Investing Cash Flow
-1.9M
↑ 11.15%
Financing Cash Flow
559.0K
↓ 133.49%
FY19Y/Y Change
Operating Cash Flow
4.8M
↓ 275.72%
Investing Cash Flow
-8.1M
↑ 318.0%
Financing Cash Flow
4.2M
↑ 650.09%
FY20Y/Y Change
Operating Cash Flow
-17.2M
↓ 457.45%
Investing Cash Flow
-2.2M
↓ 73.3%
Financing Cash Flow
7.0M
↑ 66.97%
FY21Y/Y Change
Operating Cash Flow
387.0K
↓ 102.25%
Investing Cash Flow
-34.5M
↑ 1489.72%
Financing Cash Flow
-242.0K
↓ 103.46%
FY22Y/Y Change
Operating Cash Flow
-16.6M
↓ 4386.82%
Investing Cash Flow
25.2M
↓ 173.12%
Financing Cash Flow
-241.0K
↓ 0.41%
FY23Y/Y Change
Operating Cash Flow
-37.0M
↑ 122.88%
Investing Cash Flow
99.0M
↑ 292.42%
Financing Cash Flow
-1.1M
↑ 366.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.2M
↓ 28.7%
Investing Cash Flow
-869.0K
↑ 33.28%
Financing Cash Flow
-62.0K
↓ 34.74%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.1M
↓ 18.46%
Investing Cash Flow
-666.0K
↓ 23.36%
Financing Cash Flow
3.3M
↓ 5377.42%
Q3 FY23Q/Q Change
Operating Cash Flow
-13.4M
↑ 164.62%
Investing Cash Flow
-254.0K
↓ 61.86%
Financing Cash Flow
-518.0K
↓ 115.83%
Q4 FY23Q/Q Change
Operating Cash Flow
-13.4M
↑ 0.0%
Investing Cash Flow
-254.0K
↑ 0.0%
Financing Cash Flow
-518.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Enzo Biochem Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Enzo Biochem Inc
Enzo Biochem Inc
4.67%
-15.79%
-23.81%
-69.57%
-67.16%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
1.13%
-16.13%
-1.02%
-30.71%
76.78%
Agilent Technologies Inc.
Agilent Technologies Inc.
2.42%
-8.11%
18.01%
-22.8%
84.96%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
4.08%
2.29%
14.99%
7.41%
109.35%
Danaher Corp.
Danaher Corp.
1.1%
4.75%
17.79%
-19.33%
91.02%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
5.86%
-6.0%
10.99%
-8.08%
60.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Enzo Biochem Inc
Enzo Biochem Inc
NA
NA
0.0
0.0
-0.4
-0.13
NA
1.35
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
46.49
46.49
5.05
10.51
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
28.76
28.76
2.99
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.6
37.6
2.26
21.75
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
48.58
48.58
2.63
7.58
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.24
32.24
1.22
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Enzo Biochem Inc
Enzo Biochem Inc
Buy
$57.6M
-67.16%
NA
134.17%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.9B
76.78%
46.49
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.8B
84.96%
28.76
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$233.5B
109.35%
37.6
14.69%
Danaher Corp.
Danaher Corp.
Buy
$192.3B
91.02%
48.58
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$45.2B
60.05%
32.24
9.39%

Insights on Enzo Biochem Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 8.55M → 8.02M (in $), with an average decrease of 6.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -6.61M → -3.02M (in $), with an average increase of 58.8% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 18.0% return, outperforming this stock by 41.8%

  • Vs TMO

    In the last 3 years, Enzo Biochem Inc has experienced a drawdown of -69.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 46.8%

Institutional Holdings

  • Harbert Fund Advisors Inc

    10.06%

  • Renaissance Technologies Corp

    4.73%

  • Vanguard Group Inc

    3.65%

  • BlackRock Inc

    1.86%

  • Dimensional Fund Advisors, Inc.

    0.66%

  • Geode Capital Management, LLC

    0.66%

Company Information

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Organization
Enzo Biochem Inc
Employees
179
CEO
Ms. Kara Cannon
Industry
Health Technology

Discover More

FAQs